infection (OBI) in blood donors was investigated in the Baoji area of North China, and OBI-related viral mutations in donors were characterized.
RESULTS: OBI was detected in 60 (1:1847) individual blood donors. All OBI samples were negative for hepatitis B e-antigen, and 55 were positive for anti-hepatitis B core antigen. The preS/S genes were successfully sequenced for 43 OBI samples. OBI-related S gene mutations in the major hydrophilic region were detected more frequently in blood donors with OBI than that in controls (51.16 vs. 12.96%; p < 0.01). Specifically, the incidence of five OBIrelated major hydrophilic region mutations (sS117T, sT118K, sT131N, sT134Y/L, and sD144E) was significantly higher in blood donors with OBI than in controls. In addition, the coexistence of multiple OBIrelated mutations in the major hydrophilic region was detected more frequently in donors than in controls (30.23 vs. 1.85%; p < 0.01), and preS deletions greater than 33 base pairs also were detected more frequently in blood donors with OBI than in controls.
CONCLUSION: OBI in blood donors should be addressed attentively in the Baoji area of North China, and HBV preS/S gene mutations may play an important role in OBI prevalence in the area.
T he long-lasting persistence of hepatitis B virus (HBV) genomes in the serum or liver of individuals who test negative for hepatitis B surface antigen (HBsAg) with currently available assays is termed occult HBV infection (OBI). 1 OBI can be transmitted through blood transfusion, parturition, liver transplantation, and even through close contact. 2 Immune system hypofunction and the use of immunosuppressive agents can lead to OBI reactivation and recurrence of typical serological evidence of infection. the progression of liver disease and increasing the risk of tumorigenesis. [5] [6] [7] The incidence of OBI was influenced by HBVendemic areas, the particular population studied, the public health status of the area, and screening methodology; and incidence differed extensively from previously reported values. For example, OBI detection rates have ranged from 0 to 54% in hemodialysis patients, 8 from 0.63 to 88.4% in HBV and human immunodeficiency virus co-infected patients, 9 and up to 73% (24 of 33 patients) in those with cryptogenic causes of hepatocellular carcinoma. 10 Among blood donors in recent years, the incidence of OBI has varied with the prevalence of HBV and public health conditions. Specifically, the OBI incidence was 1:27 19 To date, there has been a paucity of data from population-based investigations presenting OBI features in blood donors from North China. The clinical features and pathophysiology of HBV infection are determined by the balance between the host-immune response and viral replication competence. 20 HBsAg is the target of neutralizing antibodies and is encoded by the preS/S gene, which includes the preS1, preS2, and S genes. Mutation of the preS/S gene has been suggested as a factor that influences the balance between host and virus and is associated with OBI. 21 The region of amino acids (aa) from 99 to 169 of the S protein is termed the MHR, and it contains the major conformational epitope exposed on the external surface of the viral particle.
Immune escape mutations in the MHR are highly correlated with OBI. Major OBI-related S gene mutations documented in previous studies are as follows: sY100C, sM103I, sL109I/P, sP111L, sG112R, sS114T/N, sT115A/N, sS117T, sT118K, sP120A/Q/T, sK122R/N/I, sT123A/N/V, sC/T124S/R/Y, sP127T, sQ129N, sG130N/R, sT131N, sM133T, sF/Y134H/L, sC138Y, sT140I, sK141E, sP142L/S, sS143L/M, sD144A/E, sG145R/A, sN146S, sP151L, sA159G, and sK/R160N. [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition, preS deletions also reportedly were associated with OBI, especially those with large fragment deletions. 31, 32 In our previous studies, we demonstrated that, compared with the wild-type strain, the preS1 deletion mutant had deficient preS1 expression, significantly decreased viral messenger RNA levels, and SP II promoter activity; whereas the preS2 deletion mutant had defective preS2 expression and significantly decreased viral messenger RNA levels. 33, 34 The coexisting preS deletions and/or multiple OBI-related mutations may play coordinated roles leading to OBI, as we recently reported. 34 The objective of this study was to investigate OBI in blood donors in the Baoji area of North China and to characterize OBI-related viral mutations across the donor blood samples that had OBI identified.
MATERIALS AND METHODS

Study participants
This was a retrospective study with consecutively collected samples. In total, 110,843 blood donor plasma samples were collected from December 2011 to March 2015 at Baoji Blood Center, and 108 serum samples from adult patients who had chronic hepatitis B (CHB) with mild to moderate liver disease activity were obtained from Beijing 302 Hospital. The diagnostic criteria were based on the Management Scheme of Diagnostic and Therapy Criteria of Viral Hepatitis 35 and were described in detail in our previous study. 36 All samples were stored at 2408C until use. Blood donors and patients with CHB were identified from either the Baoji Blood Center or Beijing 302 Hospital database, and all participants provided their informed consent before enrollment in the databases. The study was approved by the ethics committees of Beijing 302 Hospital and Baoji Blood Center.
Assays for plasma or serum HBV markers
All kits and assays for HBV markers are approved by the China Food and Drug Administration. For screening of blood donors at Baoji Blood Center, HBV DNA and HBsAg were detected according to the Blood Donation Law of the People's Republic of China. HBsAg was detected using enzyme-linked immunosorbent assay kits from two manufacturers (Ke Hua Biotechnology, Inc. and Wan Tai Biotechnology, Inc.), and the detection was performed by independent technicians. HBsAg-negative status was determined by negative results from both enzyme-linked immunosorbent assay kits. A minipool nucleic acid amplification testing model was used for the Roche COBAS AmpliScreen HBV/hepatitis C virus/human immunodeficiency virus test (Roche Diagnostics), with 167 lL plasma for each sample in a 6-sample mixture. Individualdonation nucleic acid amplification testing was implemented for positive minipool samples. The lower detection limit for HBV DNA was 3.7 IU/mL. All HBsAg-negative/ HBV DNA-positive samples (i.e., OBI samples) were collected and sent to Beijing 302 Hospital for further testing.
HBsAg was quantified using a Roche Cobas e601 electrochemistry luminescence immunity analyzer and an Elecsys for HBsAg quantitation (Roche Diagnostics) with a lower detection limit of 0.05 IU/mL. Plasma or serum HBV DNA was quantified using COBAS AmpliPrep/COBAS TaqMan (Roche Diagnostics) with a lower detection limit of 20 IU/ mL (linear range). Hepatitis B e-antigen (HBeAg), anti-hepatitis B e-antigen (anti-HBe), anti-HB surface antibody (anti-HBs), and anti-hepatitis B core antigen (anti-HBc) levels were determined using a Roche Cobas e601 electrochemistry luminescence immunity analyzer, and the results were expressed either in IU/L for anti-HBs or according to a cutoff index for the remaining parameters, as we previously described. 37 All testing was implemented in the Department of Central Clinical Laboratory of Beijing 302 Hospital.
HBV preS/S gene amplification and sequencing
The complete methods are described in our previous study with modification. 38 Briefly, HBV DNA was extracted from serum, and the viral preS/S gene was amplified by nested polymerase chain reaction (PCR) with PSup3 as the upstream and downstream primers, respectively, for the second round. The PCR products were purified for direct sequencing, which was performed by a professional company (Tian Yi Hui Yuan Biotech) with an ABI 3730x1 DNA Analyzer (Applied Biosystems). Sequencing data were analyzed using the Vector NTI Suite software package (Informax) and DNASTAR software (DNASTAR, Inc.). The analyses focused on OBI-related mutations in the MHR and preS deletions. Because longer deletions usually have a greater influence on viral activity, and genotype D HBV is naturally short of 33 nucleotides in the preS1 gene compared with genotype B and C HBV, deletions longer than 33 base pairs (bp) were defined as large fragment deletions and were given special attention.
Phylogenetic analysis and multiple sequence alignment
Phylogenetic analysis was performed with MEGA 4 software for analysis of genotype and the evolutionary relationship of the preS/S genes, as we previously described. 39 The evolutionary history was inferred using the neighborjoining method. Evolutionary distances were computed using the Kimura two-parameter method and are expressed in units of the number of base substitutions per site. All positions that contained gaps and missing data were eliminated. In total, there were 1108 positions with the HBV reference sequences for multiple genotypes (A through H) available in the National Center for Biotechnology Information genotyping tool ( 
RESULTS
Detection rate of OBI in the blood donors
Of the 110,843 samples, 60 were verified as HBsAg negative (<0.05 IU/mL) and HBV DNA positive (20 IU/mL), accounting for 1:1847 of the investigated blood donors. All 60 OBI samples were negative for HBeAg, and 55 were positive for anti-HBc. Anti-HBe and anti-HBs were detected in seven and 20 individuals, respectively. Of the five anti-HBc-negative samples, none were positive for anti-HBe, and three were positive for anti-HBs. All blood donors with OBI had normal alanine and aspartate aminotransferase levels.
HBV preS/S gene amplification and genotype classification
Of the 60 OBI samples, 43 had successful amplification of the preS/S genetic region (all were negative for HBeAg, and 40 were positive for anti-HBc). In light of this result, HBV genomes from 108 adult patients with CHB from North China were collected as controls. The GenBank accession numbers for the preS/S genes from the 43 OBI 
blood donor samples are KX276958 through KX277000. The GenBank accession numbers for the HBV genomes from the 108 adult patients with CHB are FJ386574 through FJ386689, except for eight sequences from juveniles (i.e., FJ386583, FJ386584, FJ386591, FJ386598, FJ386632, FJ386636, FJ386652, and FJ386666). Information on the 43 blood donors with OBI and the 108 patients with CHB is provided in Table 2 . HBV genotype classification was determined based on phylogenetic analyses of the preS/S genetic sequences. HBV genotypes B, C, and D were detected in three, 37, and three blood donors with OBI, respectively, and in 24 patients, 83 patients, and one patient with CHB, respectively. Neighborjoining phylogenetic trees based on the 43 OBI preS/S genetic sequences and the 108 control genomes with the GenBank accession numbers are shown in Fig. 1A ,B, respectively.
Comparison of OBI-related mutations in the MHR of the S region from blood donors with OBI and controls OBI-related mutations in the MHR of the S region were detected in 22 OBI samples and 14 CHB samples. The detection rate was significantly higher in blood donors with OBI than that in controls (51.16 vs. 12.96%; p < 0.01). Specifically, the detection rates of five OBI-related mutations (sS117T, sT118K, sT131N, sT134Y/L, and sD144E) GenBank accession number, and reference sequences are marked by circles.
were significantly higher in blood donors with OBI than the rates in controls. In addition, the coexistence of multiple OBI-related MHR mutations was detected more frequently in blood donors with OBI than in controls (30.23 vs. 1.85%; p < 0.01) ( Table 3) . To aid in the comparisons, the putative aa sequences were aligned with the standard reference sequences of Genotype B (AB033554, AF100309, D00329), Genotype C (AB014381, AY123041, X04615), and Genotype D (M32138, X65259, X85254). The alignment of the 36 sequences with the OBI-related substitutions in the MHR is shown in Fig.  2 . The corresponding original alignment presenting all substitutions that differed from the majority of aa sequences of the MHR is shown in Fig. S1 (available as supporting information in the online version of this paper) for the 43 sequences from blood donors with OBI and in Fig. S2 (available as supporting information in the online version of this paper) for the 108 sequences from controls.
Comparison of preS deletions from blood donors with OBI and controls
PreS deletions were detected in samples from eight blood donors with OBI and 16 patients with CHB. Overall, the prevalence of deletions in the preS region was not significantly different between the two groups. However, deletions longer than 33 bp were detected in seven (16.28%) donors with OBI, versus six (5.60%) patients with CHB (p < 0.05). The deletion lengths were in multiples of three nucleotides for all deletion-positive sequences except for FJ386686, which had no ATG start codon until the preS2 initiation sequence, leading to deletion of the whole preS1 protein. Therefore, these preS deletions did not cause reading frame shifts.
Nucleotide sequences of the preS region were aligned with the standard reference sequences for comparison. The alignment of the 24 sequences with the preS deletions is illustrated in Fig. 3 . The location and length of each deletion are depicted in the figure. The corresponding original alignment presenting all variations that differed from the majority of nucleotide sequences is shown in Fig. S3 (available as supporting information in the online version of this paper) for the 43 sequences from blood donors with OBI and in Fig. S4 (available as supporting information in the online version of this paper) for the 108 sequences from controls.
DISCUSSION
Until now, there has been a paucity of data presenting population-based OBI incidence among blood donors in North China. In the donors described here, the OBI HBV DNA yield rate was 1:1847. This was approximately three times lower than the data from South China reported by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases of China (1:631), 19 but it was slightly higher than the data from Hong Kong Red Cross Blood Transfusion Service (1:2450) and Shenzhen Blood Center (1:3239). 13, 14 The reasons for the presence of low HBV DNA levels in the absence of detectable HBsAg among individuals with OBI remains unclear, but it is thought that both host and viral factors are important for suppressing viral replication and maintaining control of the infection. 40 The viral and host factors that contribute to OBI are numerous, complex, and vary between individuals. Possible mechanisms may include low HBsAg production, impaired HBsAg secretion, diminishing HBsAg antigenicity, and elicitation of low-affinity or non-neutralizing antibodies that interfere with detection by the HBsAg reagent. OBI-related mutations in the MHR of the HBV S gene mainly attenuate the antigenicity of B-cell epitopes or impact the detection of HBsAg by commercial assays, as reported by El Chaar and colleagues. 41 By contrast, HBV preS deletions may attenuate HBsAg expression and secretion. 31, 33, 34 Based on our understanding, OBI can be roughly classified into two patterns, that is, an immune control-dominant pattern and an immune escapedominant pattern. In the latter pattern, HBV preS/S gene mutations play a critical role. In our study, the detection rate for OBI-related MHR mutations was significantly higher in blood donors with OBI than that in patients with Each dot represents a common amino acid. OBI-related substitutions are marked with capital letters for blood donors with OBI and patients with HB (the corresponding original alignment presenting all substitutions that differed from the majority of amino acid sequences in the MHR is shown in Fig. S1 for the 43 sequences from blood donors with OBI and in Fig. S2 for the 108 sequences from controls).
CHB, suggesting that at least some of the blood donors with OBI displayed the immune escape-dominant pattern. In these cases, HBV mutants develop to adapt to environmental pressure, and the mutant viruses may maintain replication competency to a comparable wild-type virus, which provides the basis for persistence and transmission of the mutant viruses. 16, 42 Two classical immune escape mutations in the MHR are sG145R and sP120T. 43 In this study, the frequencies of both mutations were low, suggesting that these two classical mutations could be better detected due to the improvement in HBsAg detection reagents and that other immune escape mutations may take over the position. The coexistence of multiple OBIrelated mutations in the MHR was detected much more frequently in blood donors who had OBI compared with controls, suggesting that mutations may play coordinated roles leading to OBI. Notably, the OBI-related sT131N mutation was detected in four (9.30%) of the blood donors with OBI compared with none of the patients with CHB (p 5 0.02). In addition, the OBI-related sT129N mutation was detected in three (6.98%) blood donors with OBI but in only one patient (0.93%) with CHB (p 5 0.07). Both sT131N and sT129N may introduce an additional Nglycosylation site in the MHR, which may contribute to immune escape by diminishing the antigenicity of HBsAg, shielding the "a" determinant from neutralizing antibody, and eliciting low-affinity or non-affinity antibodies that interfere with detection by the HBsAg reagent. 30, 34, 44, 45 The detection rates of OBI-related mutations in the MHR were 55.0% ( Together, these results suggest that anti-HBs status has little value in screening for OBI in blood donors. Interestingly, five of the 60 blood donors with OBI were negative for anti-HBc, which is usually detected in HBV-infected individuals. This result is consistent with a previous study in which OBI was classified into seropositive (anti-HBc positive) and seronegative (anti-HBc negative). 16 Therefore, an anti-HBc-negative result was not an absolutely exclusive measure of HBV infection, and HBV DNA detection is essential for blood screening. In some areas of China, however, HBV DNA detection is advocated, but not compulsory, for blood donor screening. This brings with it a risk of HBV transmission through improperly tested blood transfusion.
The preS gene is comprised of the preS1 (nt 2848-3204 for HBV Genotypes B and C) and preS2 (nt 3205-154) regions. The preS1 region covers a large proportion of the SPII promoter (nt 2809-3152). Large-fragment deletions in the preS1 region have been shown to greatly attenuate SPII activity and decrease HBsAg production. 34 Deletions in preS2 may produce truncated M protein, which is retained and accumulates in the endoplasmic reticulum, and may display transcriptional activation properties and transforming potential. 21 In this study, deletions longer than 33 bp in the preS fragment were significantly more frequent in blood donors with OBI than that in controls, and most deletions were concomitant with OBI-related mutations in the MHR, suggesting that preS deletions were likely responsible for some cases of OBI in the blood donors and might play coordinated roles with OBI-related mutations. This is a retrospective study. According to the relevant regulations in China, HBsAg-positive samples from blood donor candidates are not tested for HBV DNA and are only preserved for a short time. Because we used patients with CHB as a control group in some previous OBI studies, 46, 47 patients from North China with CHB who had mild to moderate inflammatory activity were also used as It is a critical point to specifically amplify HBV preS/S genes in samples that have low viral loads. We developed a highly sensitive, one-tube, nested PCR assay for the amplification of HBV RT/preS/S genes, which allowed us to analyze samples with quite low viral loads (as low as 20 IU/mL). The method has acquired a Chinese invention patent (ZL200910092331.1) and was verified as reliable in our previous analyses of HBV genetic variations, 33, 34, [36] [37] [38] [39] including successfully amplified and cloned HBV RT/S gene from a sample with undetectable HBV DNA in the clinic. 51 In this study, we employed direct PCR sequencing, which could detect the presence of 20% or more variant HBV quasispecies. 52 Some other methods, such as ultra-deep pyrosequencing, may detect a much smaller fraction of HBV subpopulations, but they require higher costs, and the clinical relevance of a tiny minority of variants might be uncertain.
In conclusion, for the first time, we have clarified the incidence of OBI in blood donors from the Baoji area of North China through a population-based investigation. The results suggest that immune escape mutations in the HBV preS/S region are important factors related to the presentation of OBI. This study provides new insights into the features of OBI among blood donors that will be helpful for the management of HBV transmission through blood transfusion.
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